DMIIU
Drugs Made In America Acquisition II Corp.
Key Financials
Net Income
$4.2M
↑ 2859.7%
Operating Income
$-488385
↓ 221.9%
Total Liabilities
$17.8M
↑ 6886.7%
Cash & Equivalents
$223.00
N/A
Total Assets
$505.0M
↑ 365643.3%
Operating Cash Flow
$-1018231.00
↓ 424.1%
Shareholders' Equity
$-17774827.00
↓ 15128.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/14/2026 | View on SEC |
| 8-K | 4/28/2026 | View on SEC |
| 10-K | 4/15/2026 | View on SEC |
| 8-K | 4/3/2026 | View on SEC |
| NT 10-K | 4/1/2026 | View on SEC |
| 8-K | 3/17/2026 | View on SEC |
| 8-K | 3/6/2026 | View on SEC |
| 8-K | 3/6/2026 | View on SEC |
| 10-Q | 11/18/2025 | View on SEC |
| 8-K | 11/18/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DMIIU |
| Company Name | Drugs Made In America Acquisition II Corp. |
| CIK | 2040475 |
| Sector | Blank Checks |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 6770 |
| SIC Description | Blank Checks |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 954-870-3104 |